Supplementary Information

Data on the clinical responses of conjugates per tumour type.

1. HPMA Copolymer-doxorubicin (PK1; FCE28068) [4,19]

Table S1. Data relating to clinical trials (Phase I [Ph-I], Phase II [Ph-II]) of PK1; [Total number of patients enrolled for the study 98 [a]].

tumour type	No. of patients per tumour total (Ph I/Ph II)	Clinical responses [b] total (Ph I/Ph II)					Tumour response rate [c] (%) total (Ph I/Ph II)
		No. of SD	No. of PR	No. of MR	No. of CR	No. of NR	
Lung	31[(2/29(21) *]	8[-/8]	5[2/3]	-	-	10[0/10]	57[100/52]
Breast	20[3/17(14) *]	5[-/5]	3[-/3]	1[1/-]	-	8[2/6]	53[33/57]
Colon and/or rectum	24[8/16]	-	-	1[1/-]	-	23[7/16]	4[4/-]
Adenocarcinoma (Unknown primary)	5[5/-]	-	-	-	-	5[5/-]	0
Ovary	3[3/-]	-	-	-	-	3[3/-]	0
Liver	3[3/-]	-	-	-	-	3[3/-]	0
Pancreas	3[3/-]	-	-	-	-	3[3/-]	0
Urinary	3[3/-]	-	-	-	-	3[3/-]	0
Head/Neck and brain	3[3/-]	-	-	-	-	3[3/-]	0
Mesothelioma	2[2/-]	-	-	-	-	2[2/-]	0
Oesophagus, stomach and intestine	1[1/-]	-	-	-	-	1[1/-]	0

Notes: [a] Indicates number of patients considered for the clinical evaluation; [b] clinical responses is the total SD, Stable disease; PR, Partial response; MR, Minor response; CR, Complete response; NR, No response; [c] Tumour response rate (%) is the added responses (SD + PR + MR + CR) per tumour type; * Indicates number of patients evaluated for the tumour responses.

2. HPMA Copolymer-doxorubicin-galactosamine (PK2; FCE28069) [20]

Table S2. Data relating to clinical trials (Phase I [Ph-I]) of PK2; [Total number of patients enrolled for the study 31(18) [a]].

Tumour type	No. of patients per tumour (Ph I)	Clinical responses [b] (Ph I)					Tumour response rate [c] (%) (Ph I)
		No. of SD	No. of PR	No. of MR	No. of CR	No. of NR	
Liver	25	-	2	1	-	22	12
Colon and/or rectum	6	-	-	-	-	6	0

Notes: [a] Indicates number of patients considered for the clinical evaluation; [b] clinical responses is the total SD, Stable disease; PR, Partial response; MR, Minor response; CR, Complete response; NR, No response; [c] Tumour response rate (%) is the added responses (SD + PR + MR + CR) per tumour type.

3. Carboxymethyldextran-exatecan; DE-310 [21]

Table S3. Data relating to clinical trials (Phase I [Ph-I]) of DE-310; [Total number of patients enrolled for the study 29(27) [a]].

Tumour type	No. of patients per tumour (Ph I)	Clinical responses [b] (Ph I)					Tumour response rate [c] (%) (Ph I)
		No. of SD	No. of PR	No. of MR	No. of CR	No. of NR	
Adenocarcinoma (Unknown primary)	2	1	-	-	1	0	100
Pancreas	3	2	1	-	-	0	100
Urinary	1	1	-	-	-	0	100
Cervix	1	1	-	-	-	0	100
Ovary	1	1	-	-	-	0	100
Colon and/or rectum	6	4	-	-	-	2	67
Lung	3	2	-	-	-	1	67
Skin	6	2	-	-	-	4	33
Soft tissue sarcoma	3	-	-	-	-	3	0
Oesophagus, stomach and intestine	3	-	-	-	-	3	0

Notes: [a] Indicates number of patients considered for the clinical evaluation; [b] clinical responses is the total SD, Stable disease; PR, Partial response; MR, Minor response; CR, Complete Response; NR, No response; [c] Tumour response rate (%) is the added responses (SD + PR + MR + CR) per tumour type.

4. Delimotecan; MEN 4901/T-0128 [22]

Table S4. Data relating to clinical trials (Phase I [Ph-I]) of MEN 4901/T-0128; [Total number of patients enrolled for the study 22 [a]].

Tumour type	No. of patients per tumour (Ph I)	Clinical responses [b] (Ph I)					Tumour response rate [c] (%) (Ph I)
		No. of SD	No. of PR	No. of MR	No. of CR	No. of NR	
Head/Neck and brain	2	-	1	-	-	1	50
Colon and/or rectum	7	-	1	-	-	6	14
Mesothelioma	3	-	-	-	-	3	0
Urinary	1	-	-	-	-	1	0
Skin	1	-	-	-	-	1	0
Adenoid cystic	1	-	-	-	-	1	0
Oesophagus, stomach and intestine	2	-	-	-	-	2	0
Adenocarcinoma (Unknown primary)	2	-	-	-	-	2	0
Lung	2	-	-	-	-	2	0
Kidney	1	-	-	-	-	1	0
Sarcoma (Unknown)	1	-	-	-	-	1	0

Notes: [a] Indicates number of patients considered for the clinical evaluation; [b] clinical responses is the total SD, Stable disease; PR, Partial response; MR, Minor response; CR, Complete response; NR, No response; [c] Tumour response rate (%) is the added responses (SD + PR + MR + CR) per tumour type.

5. Poly-L-glutamic acid-camptothecin; PGA-CPT; CT-2106 [23]

Table S5. Data relating to clinical trials (Phase I [Ph-I]) of CT-2106; [Total number of patients enrolled for the study 26(25) [a]].

Tumour type	No of patients per tumour (Ph I)	Clinical responses [b] (Ph I)					Tumour response rate [c] (%) (Ph I)
		No. of SD	No. of PR	No. of MR	No. of CR	No. of NR	
Breast	4	1	-	-	-	3	25
Skin	14	2	-	-	-	12	14
Bone	1	-	-	-	-	1	0
Pancreas	2	-	-	-	-	2	0
Lung	3	-	-	-	-	3	0
Colon and/or rectum	1	-	-	-	-	1	0
Squamous cell carcinoma	1	-	-	-	-	1	0

Notes: [a] Indicates number of patients considered for the clinical evaluation; [b] clinical responses is the total SD, Stable disease; PR, Partial response; MR, Minor response; CR, Complete response; NR, No response; [c] Tumour response rate (%) is the added responses (SD + PR + MR + CR) per tumour type.

6. Poly-L-glutamic acid-paclitaxel; PGA-PTX; CT-2103; XYOTAX; OPAXIO® [5,6,18,24–33]

Table S6a. Data relating to clinical trials (Phase I [Ph-I], Phase II [Ph-II], Phase III [Ph-III]) of CT-2103 (PGA-Paclitaxel); [Total number of patients enrolled for the study 1951 [a]].

Tumour type	No. of patients per tumour total (Ph I/Ph II/Ph III)	Clinical responses [b] total (Ph I/Ph II/Ph III)						Tumour response rate [c] (%) total (Ph I/Ph II/Ph III)
		No. of SD	No. of PR	No. of MR	No. of CR	No. of OS	No. of NR	
Breast	18[-/18/-]	2[-/2/-]	4[-/4/-]	4[-/4/-]	-	-	8[-/8/-]	56[-/56/-]
Ovary	99[-/99/-]	32[-/32/-]	10[-/10/-]	-	-	-	57[-/57/-]	42[-/42/-]
Mesothelioma	3[3/-/-]	-	-	1[1/-/-]	-	-	2[2/-/-]	33[33/-/-]
Lung	1798[13/-/1785]	-	13[NA/NA/NA]	1[NA/NA/NA]	-	507[-/-/507]	1277[NA/NA/NA]	30[NA/NA/NA]
Oesophagus, stomach and intestine	24[-/24/-]	-	-	1[-/1/-]	4[-/4/-]	-	19[-/19/-]	21[-/21/-]
Kidney	3[3/-/-]	-	-	-	-	-	3[3/-/-]	0
Sarcoma (Unknown)	1[1/-/-]	-	-	-	-	-	1[1/-/-]	0
Cervix	1[1/-/-]	-	-	-	-	-	1[1/-/-]	0
Adrenal	1[1/-/-]	-	-	-	-	-	1[1/-/-]	0
Unknown primary	3[3/-/-]	-	-		-	-	3[3/-/-]	0
Colon and/or rectum	8[8/-/-]	-	-	-	-	-	8[8/-/-]	0

Notes: [a] Indicates number of patients considered for the clinical evaluation; [b] clinical responses is the total SD, Stable disease; PR, Partial response; MR, Minor response; CR, Complete response; OS, Overall survival; NR, No response; [c] Tumour response rate (%) is the added responses (SD + PR + MR + CR + OS) per tumour type. NA, Not available.

Table S6b. *Cont.* [Total number of patients enrolled for the study 22 [a]].

Tumour type	No. of patients per tumour	Clinical responses [b]					Tumour response rate [c] (%)
		No. of SD	No. of PR	No. of MR	No. of CR	No. of NR	
Solid tumours *	23	12	3	-	-	12	65

Notes: * Solid tumours includes-Lung (6); Head/Neck and brain (6); Ovary (3); Pancreas (2); Oesophagus, stomach and intestine (1); Breast (1); Kidney (1); Unknown primary (1); Colon and/or rectum (2); [a] Indicates number of patients considered for the clinical evaluation; [b] clinical responses is the total SD, Stable disease; PR, Partial response; MR, Minor response; CR, Complete response; NR, No response; [c] Tumour response rate (%) is the added responses (SD + PR + MR + CR) per tumour type.

7. HPMA Copolymer-carboplatin; HPMA-Carboplatin; AP5280 [34]

Table S7. Data relating to clinical trials (Phase I [Ph-I]) of AP5280; [Total number of patients enrolled for the study 29(19) [a]].

Tumour type	No. of patients per tumour (Ph I)	Clinical responses [b] (Ph I)					Tumour response rate [c] (%) (Ph I)
		No. of SD	No. of PR	No. of MR	No. of CR	No. of NR	
Lung	4	2	-	-	-	2	50
Ovary	2	1	-	-	-	1	50
Colon and/or rectum	12	2	-	-	-	10	17
Kidney	3	-	-	-	-	3	0
Oesophagus, stomach and intestine	3	-	-	-	-	3	0
Head/Neck and brain	1	-	-	-	-	1	0
Pancreas	2	-	-	-	-	1	0
Skin	2	-	-	-	-	2	0

Notes: [a] Indicates number of patients considered for the clinical evaluation; [b] clinical responses is the total SD, Stable disease; PR, Partial response; MR, Minor response; CR, Complete response; NR, No response; [c] Tumour response rate (%) is the added responses (SD + PR + MR + CR) per tumour type.

8. HPMA Copolymer-platinate; HPMA-Pt; AP5346 [35]

Table S8. Data relating to clinical trials (Phase I [Ph-I]) AP5346; [Total number of patients enrolled for the study 26 [a]].

Tumour type	No. of patients per tumour (Ph I)	Clinical responses [b] (Ph I)					Tumour response rate [c] (%) (Ph I)
		No. of SD	No. of PR	No. of MR	No. of CR	No. of NR	
Cervix	1	1	-	-	-	0	100
Oesophagus, stomach and intestine	1	1	-	-	-	0	100
Skin	5	1	1	-	-	3	40
Ovary	4	-	1	-	-	3	25
Breast	4	-	-	-	-	4	0
Adenocarcinoma (Unknown primary)	3	-	-	-	-	3	0
Prostate	2	-	-	-	-	2	0
Lung	1	-	-	-	-	1	0
Pancreas	1	-	-	-	-	1	0
Kidney	1	-	-	-	-	1	0
Head/Neck and brain	1	-	-	-	-	1	0
Bone	1	-	-	-	-	1	0
Urinary	1	-	-	-	-	1	0

Notes: [a] Indicates number of patients considered for the clinical evaluation; [b] clinical responses is the total SD, Stable disease; PR, Partial response; MR, Minor response; CR, Complete response; NR, No response; [c] Tumour response rate (%) is the added responses (SD + PR + MR + CR) per tumour type.

9. HPMA copolymer-paclitaxel; HPMA-PTX; PNU166945 [36]

Table S9. Data relating to clinical trials (Phase I [Ph-I]) PNU166945 (HPMA-PTX); [Total number of patients enrolled for the study 12 [a]].

Tumour type	No. of patients per tumour (Ph I)	Clinical responses [b] (Ph I)					Tumour response rate [c] (%) (Ph I)
		No. of SD	No. of PR	No. of MR	No. of CR	No. of NR	
Solid tumours *	12	2	1	-	-	9	25

Notes: * Solid tumours includes-Ovary (4); Breast (2); Colon and/or rectum (2); Lung (1); others (3); [a] Indicates number of patients considered for the clinical evaluation; [b] clinical responses is the total SD, Stable disease; PR, Partial response; MR, Minor response; CR, Complete response; NR, No response; [c] Overall tumour response rate (%) is the added responses (SD + PR + MR + CR) per tumour type; A clinical response per tumour type has not been mentioned in this respective study.

10. HPMA Copolymer-camptothecin; HPMA-CPT; PNU166148 [37–39]

Table S10. Data relating to clinical trials [(Phase I [Ph-I]) PNU166148 (HPMA-PTX); [Total number of patients enrolled for the study 48(40) [a]].

Tumour type	No. of patients per Tumour (Ph I)	Clinical responses [b] (Ph I)					Tumour response rate [c] (%) (Ph I)
		No. of SD	No. of PR	No. of MR	No. of CR	No. of NR	
Solid tumours *	40	5	-	1	-	34	15

Notes: * Solid tumours includes-Colon and/or rectum (18); Ovary (2); Oesophagus, stomach and intestine (4); Unknown primary (4); Head/Neck and brain (2); Lung (6); Kidney (3); Adrenal (1); Cervix (1); Bone (1); Mesothelioma (1); Prostate (1); Sarcoma (3); [a] Indicates number of patients considered for the clinical evaluation; [b] clinical responses is the total SD, Stable disease; PR, Partial response; MR, Minor response; CR, Complete response; NR, No response; [c] Overall tumour response rate (%) is the added responses (SD + PR + MR + CR) per tumour type; A clinical response per tumour type has not been mentioned in this respective study.

11. Polyethylene-camptothecin; PEG-CPT; EZN246; Pegmaotecan; Prothecan™ [40–42]

Table S11. Data relating to clinical trials (Phase I [Ph-I], Phase II [Ph-II]) of PEG-CPT; [Total number of patients enrolled for the study 64(63) [a]].

Tumour type	No. of patients per tumour total (Ph I/Ph II)	Clinical responses [b] total (Ph I/Ph II)					Tumour response rate [c] (%) total (Ph I/Ph II)
		No. of SD	No. of PR	No. of MR	No. of CR	No. of NR	
Bone	1[1/-]	-	-	1[1/-]	-	0[0/-]	100[100/-]
Oesophagus, stomach and intestine	42[7/35]	14[-/14]	5[-/5]	3[2/1]	-	20[5/15]	52[29/57]
Unknown primary	5[5/-]	-	-	1[1/-]	-	4[4/-]	20[20/-]
Lung	7[7/-]	-	1[1/-]	-	-	6[6/-]	14[14/-]
Colon and/or rectum	25[25/-]	-	-	-	-	25[25/-]	0
Liver	3[3/-]	-	-	-	-	3[3/-]	0
Head/Neck and brain	2[2/-]	-	-	-	-	2[2/-]	0
Mesothelioma	1[1/-]	-	-	-	-	1[1/-]	0
Ovary	1[1/-]	-	-	-	-	1[1/-]	0
Pancreas	4[4/-]	-	-	-	-	4[4/-]	0
Sarcoma (Unknown)	2[2/-]	-	-	-	-	2[2/-]	0
Breast	1[1/-]	-	-	-	-	1[1/-]	0
Lymphoma	1[1/-]	-	-	-	-	1[1/-]	0
Skin	2[2/-]	-	-	-	-	2[2/-]	0
Leiomyosarcoma	2[2/-]	-	-	-	-	2[2/-]	0

Notes: [a] Indicates number of patients considered for the clinical evaluation; [b] clinical responses is the total SD, Stable disease; PR, Partial response; MR, Minor response; CR, Complete response; NR, No response; [c] Tumour response rate (%) is the added responses (SD + PR + MR + CR) per tumour type.

12. Polyethylene Glycol-Paclitaxel; PEG-PTX [43]

Table S12. Data relating to clinical trials (Phase I [Ph-I]) of PEG-PTX; [Total number of patients enrolled for the study 13 [a]].

Tumour type	No. of patients per tumour (Ph I)	Clinical responses [b] (Ph I)					Tumour response rate [c] (%) (Ph I)
		No. of SD	No. of PR	No. of MR	No. of CR	No. of NR	
Solid tumours *	13	NA				NC	NC

Notes: * Solid tumours includes-Colon and/or rectum (3); Breast (2); Neuroendocrine (2); Lung (1); Prostrate (1); Others (4); [a] Indicates number of patients considered for the clinical evaluation; [b] clinical responses is the total SD, Stable disease; PR, Partial response; MR, Minor response; CR, Complete response; NR, No response; [c] Tumour response rate (%) is the added responses (SD + PR + MR + CR) per tumour type; NA-Not available; NC-Not calculated.

13. Multiarm-Polyethylene-SN38; EZN-2208 [44,45]

Table S13. Data relating to clinical trials (Phase I [Ph-I], Phase II [Ph-II]) of PEG-CPT; [Total number of patients enrolled for the study 264(196) [a]].

Tumour type	No. of patients per tumour total (Ph I/Ph II)	Clinical responses [b] total (Ph I/Ph II)					Tumour response rate [c] (%) total (Ph I/Ph II)
		No. of SD	No. of PR	No. of MR	No. of CR	No. of NR	
Urinary	1[1/-]	1[1/-]	-	-	-	0[0/-]	100[100/-]
Oesophagus, stomach and intestine	3[3/-]	2[2/-]	-	-	-	1[1/-]	67[67/-]
Breast	3[3/-]	2[2/-]	-	-	-	1[1/-]	67[67/-]
Lung	2[2/-]	1[1/-]	-	-	-	1[1/-]	50[50/-]
Pancreas	3[3/-]	1[1/-]	-	-	-	2[2/-]	33[33/-]
Colon and/or rectum	236[25/211(192) *]	32[12/20]	4[-/4]	-	-	181[13/168]	17[48/13]
Carcinoid	1[1/-]	-	-	-	-	1[1/-]	0
Ovary	1[1/-]	-	-	-	-	1[1/-]	0
Prostate	1[1/-]	-	-	-	-	1[1/-]	0
Soft tissue sarcoma	1[1/-]	-	-	-	-	1[1/-]	0

Notes: [a] Indicates number of patients considered for the clinical evaluation; [b] clinical responses is the total SD, Stable disease; PR, Partial response; MR, Minor response; CR, Complete response; NR, No response; [c] Tumour response rate (%) is the added responses (SD + PR + MR + CR) per tumour type. * Indicates number of patients evaluated for the tumour responses.

14. Multiarm-Polyethylene glycol-Pacliaxtel; PEG-PTX; NKTR-102 [46–48]

Table S14. Data relating to clinical trials (Phase I [Ph-I], Phase II [Ph-II]) NKTR-102; [Total number of patients enrolled for the study 127(125) [a]].

Tumour type	No. of patients per tumour total (Ph I/Ph II)	Clinical responses [b] total (Ph I/Ph II)					Tumour response rate [c] (%) total (Ph I/Ph II)
		No. of SD	No. of PR	No. of MR	No. of CR	No. of NR	
Solid tumours *	125[32/68]	28[-/28]	24[7/17]	6[6/-]	2[2/-]	65[8/23]	48[47/66]

Notes: * Solid tumours includes-Ovary; Breast; Adrenal; Oesophagus, stomach and intestine; Lymphoma; Lung; Cervix; Head/Neck and brain; Urinary; [a] Indicates number of patients considered for the clinical evaluation; [b] clinical responses is the total SD, Stable disease; PR, Partial response; MR, Minor response; CR, Complete response; NR, No response; [c] Tumour response rate (%) is the added responses (SD + PR + MR + CR) per tumour type; A clinical response per tumour type has not been mentioned in this respective study.

15. Multiarm-Polyethylene glycol-docetaxel; NKTR-105 [50]

NKTR-105 was clinically evaluated in [Phase-I] trials involving 17 patients with different solid tumours. The data of this study was not available.

Table S15. Data on clinical trials ([Phase I [Ph-I]) NKTR-105; [Total number of patients enrolled for the study 17 [a]].

Tumour type	No. of patients per tumour (Ph I)	Clinical responses [b] (Ph I)					Tumour response rate [c] (%) (Ph I)
		No. of SD	No. of PR	No. of MR	No. of CR	No. of NR	
NA	17	NA	NA	NA	NA	NC	NC

Notes: [a] Indicates number of patients considered for the clinical evaluation; [b] clinical responses is the total SD, Stable disease; PR, Partial response; MR, Minor response; CR, Complete response; NR, No response; [c] Tumour response rate (%) is the added responses (SD + PR + MR + CR) per tumour type; NA, Not available; NC, Not calculated.

16. PHF-Camptotecin; PHF-CPT; MER-1001; XMT-1001 [51]

Table S16. Data relating to clinical trials (Phase I [Ph-I]) XMT-1001; [Total number of patients enrolled for the study 49(46) [a]].

Tumour type	No. of patients per tumour (Ph I)	Clinical responses [b] (Ph I)					Tumour response rate [c] (%) (Ph I)
		No. of SD	No. of PR	No. of MR	No. of CR	No. of NR	
Skin	2	1	-	-	-	1	50
Lung	7	3	-	-	-	4	43
Solid tumours (Unspecified)	8	3	-	-	-	5	38
Ovary	3	1	-	-	-	2	33
Oesophagus, stomach and intestine	3	1	-	-	-	2	33
Colon and/or rectum	11	2	-	-	-	9	18
Pancreas	9	1	-	-	-	8	11
Breast	4	-	-	-	-	4	0
Unknown primary	2	-	-	-	-	2	0

Notes: [a] Indicates number of patients considered for the clinical evaluation; [b] clinical responses is the total SD, Stable disease; PR, Partial response; MR, Minor response; CR, Complete response; NR, No response; [c] Tumour response rate (%) is the added responses (SD + PR + MR + CR) per tumour type.

17. Cyclodextrin-Camptothecin; CRLX101; IT-101 [52]

Table S17. Data relating to clinical trials (Phase I [Ph-I]) IT-101; [Total number of patients enrolled for the study 62 [a]].

Tumour type	No. of patients per tumour (Ph I)	Clinical responses [b] (Ph I)					Tumour response rate [c] (%) (Ph I)
		No. of SD	No. of PR	No. of MR	No. of CR	No. of NR	
Lung	27	16	-	-		11	59
Solid tumours *	35	28	-	-	-	7	80

Notes: * Solid tumours includes-Pancreas (11); Head/Neck and brain (4); Kidney (4); Ovary (3); Breast (3); Cervix (2); Colon and/or rectum (1); Oesophagus, stomach and intestine (1); Liver (5); Urinary (1); [a] Indicates number of patients considered for the clinical evaluation; [b] clinical responses is the total SD, Stable disease; PR, Partial response; MR, Minor response; CR, Complete response; NR, No response; [c] Tumour response rate (%) is the added responses (SD + PR + MR + CR) per tumour type.

18. Hyaluronic Acid-Paclitaxel (ONCOFID-P™) [53]

Table S18. Data relating to clinical trials (Phase I [Ph-I]) ONCOFID-P™; [Total number of patients enrolled for the study 16(15) [a]].

Tumour type	No. of patients per tumour (Ph I)	Clinical responses [b] (Ph I)					Tumour response rate [c] (%) (Ph I)
		No. of SD	No. of PR	No. of MR	No. of CR	No. of NR	
Urinary	15	-	-	-	9	6	60

Notes: [a] Indicates number of patients considered for the clinical evaluation; [b] clinical responses is the total SD, Stable disease; PR, Partial response; MR, Minor response; CR, Complete Response; NR, No response; [c] Tumour response rate (%) is the added responses (SD + PR + MR + CR) per tumour type.

19. Oxidized Dextran-Doxorubicin; OXD-DOX (AD-70) [54]

Table S19. Data relating to clinical trials (Phase I [Ph-I]) AD-70 (OXD-DOX); [Total number of patients enrolled for the study 13 [a]].

Tumour type	No. of patients per tumour (Ph I)	Clinical responses [b] (Ph I)					Tumour response rate [c] (%) (Ph I)
		No. of SD	No. of PR	No. of MR	No. of CR	No. of NR	
Colon and/or rectum	6	1	-	-	-	5	17
Oesophagus, stomach and intestine	2	-	-	-	-	2	0
Lung	2	-	-	-	-	2	0
Urinary	1	-	-	-	-	1	0
Head/Neck and brain	1	-	-	-	-	1	0
Skin	1	-	-	-	-	1	0

Notes: [a] Indicates number of patients considered for the clinical evaluation; [b] clinical responses is the total SD, Stable disease; PR, Partial response; MR, Minor response; CR, Complete Response; NR, No response; [c] Tumour response rate (%) is the added responses (SD + PR + MR + CR) per tumour type.